DPP-4 inhibitors: What may be the clinical differentiators?

Diabetes Research and Clinical Practice

Volumn 90, Issue 2, 2010, Pages 131-140

  Gerich, John ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Dipeptidyl peptidase 4; DPP 4; Gliptins; GLP 1; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; CYTOKINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; KETOCONAZOLE; LINAGLIPTIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFECTION; INFECTION RISK; INSULIN RELEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PAIN; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PROTEIN EXPRESSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; WOUND HEALING;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENERGY INTAKE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INTESTINAL MUCOSA; NEURONS; NITRILES; PIPERIDINES; PURINES; PYRAZINES; PYRROLIDINES; QUINAZOLINES; TRIAZOLES; URACIL;

EID: 77957750184     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.07.006     Document Type: Review

References (87)

1. World Health Organization. Fact sheet no. 312, Diabetes. Available from: ; November 2009 [accessed 04.10]. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
2. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
3. Stettler C., Allemann S., Jüni P., Cull C.A., Holman R.R., Egger M., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006, 152:27-38.
4. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group.
5. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
6. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
7. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
8. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl. 2):B21-29.
9. International Diabetes Federation. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation, 2005. Available from: [accessed 06.10]. http://www.idf.org/webdata/docs/IDF%2520GGT2D.pdf.
10. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. Eur Heart J. 2007;28:88-136.
11. Standards of medical care in diabetes - 2009. Diabetes Care 2009, 32(Suppl. 1):S13-61. American Diabetes Association.
12. American College of Endocrinology American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002, 8(Suppl. 1):1-7.
13. Hoerger T.J., Segel J.E., Gregg E.W., Saaddine J.B. Is glycemic control improving in U.S. adults?. Diabetes Care 2008, 31:81-86.
14. Orozco-Beltrán D, Gil-Guillen V.F., Quirce F., Navarro-Perez J., Pineda M., Gomez-de-la-Camara A. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract 2007, 61:909-915.
15. Jenssen T.G., Tonstad S., Claudi T., Midthjell K., Cooper J. The gap between guidelines and practice in the treatment of type 2 diabetes: a nationwide survey in Norway. Diabetes Res Clin Pract 2008, 80:314-320.
16. Bryant W., Greenfield J.R., Chisholm D.J., Campbell L.V. Diabetes guidelines: easier to preach than to practise?. Med J Aust 2006, 185:305-309.
17. Kogan A.J. Overcoming obstacles to effective care of type 2 diabetes. Am J Manag Care 2009, 15:S255-S262.
18. Koro C.E., Lee B.H., Bowlin S.J. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009, 31:2608-2617.
19. Peters A.L. Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med 2009, 76(Suppl. 5):S20-S27.
20. Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
21. Pollack M.F., Purayidathil F.W., Bolge S.C., Williams S.A. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract 2010, 87:204-210.
22. Yang Y., Thumula V., Pace P.F., Banahan B.F., Wilkin N.E., Lobb W.B. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009, 31:2178-2188.
23. Yeaw J., Benner J.S., Walt J.G., Sian S., Smith D.B. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009, 15:728-740.
24. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
25. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
26. Maedler K., Carr R.D., Bosco D., Zuellig R.A., Berney T., Donath M.Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005, 90:501-506.
27. Kefas B.A., Cai Y., Kerckhofs K., Ling Z., Martens G., Heimberg H., et al. Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 2004, 68:409-416.
28. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
29. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
30. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
31. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
32. Knapper J.M., Heath A., Fletcher J.M., Morgan L.M., Marks V. GIP and GLP-1(7-36) amide secretion in response to intraduodenal infusions of nutrients in pigs. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995, 111:445-450.
33. Parker H.E., Reimann F., Gribble F.M. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 2010, 12:e1.
34. Girard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 2008, 34:550-559.
35. Niijima A. Neural mechanisms in the control of blood glucose concentration. J Nutr 1989, 119:833-840.
36. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004, 287:E199-206.
37. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
38. Thomas L., Eckhardt M., Langkopf E., Tadayyon M., Himmelsbach F., Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008, 325:175-182.
39. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214:829-835.
40. Neumiller J.J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009, 49(Suppl. 1):S16-29.
41. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993, 76:912-917.
42. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007, 30:1335-1343.
43. de Valk H.W. DPP-4 inhibitors and combined treatment in type 2 diabetes: Re-evaluation of clinical success and safety. Rev Diabet Stud 2007, 4:126-133.
44. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
45. Heise T., Graefe-Mody E.U., Hüttner S., Ring A., Trommeshauser D., Dugi K.A. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009, 11:786-794.
46. White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc 2009, 49(Suppl. 1):S30-S40.
47. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, doi: 10.1002/14651858.CD006739.pub2.
48. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2639.
49. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
50. Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R., et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411.
51. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008, 31:2315-2317. Alogliptin Study 010 Group.
52. Del Prato S, Barnett A, Huismann H, Neubacher D, Woerle H-J, Dugi KA. Linagliptin monotherapy improves glycemic control and measures of beta-cell function in type 2 diabetes. Poster 695-P, presented at the American Diabetes Association 70th Scientific Sessions, Orlando, Florida, June 2010.
53. Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:537-550.
54. Bosi E., Dotta F., Jia Y., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515.
55. DeFronzo R.A., Hissa M.N., Garber A.J., Luiz Gross J., Yuyan Duan R., Ravichandran S., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655.
56. Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63:46-55. Alogliptin Study 008 Group.
57. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA et al. Efficacy and safety of linagliptin in type 2 diabetes inadequately controlled on metformin monotherapy. Poster 579-P, presented at the American Diabetes Association 70th Scientific Sessions, Orlando, Florida, June 2010.
58. Zeender E., Maedler K., Bosco D., Berney T., Donath M.Y., Halban P.A. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004, 89:5059-5066.
59. Xu L., Man C.D., Charbonnel B., Meninger G., Davies M.J., Williams-Herman D., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008, 10:1212-1220.
60. Pratley R.E., Schweizer A., Rosenstock J., Foley J.E., Banerji M.A., Pi-Sunyer F.X., et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008, 10:931-938.
61. Deacon C.F., Holst J.J. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010, 19:133-140.
62. Hüttner S., Graefe-Mody E.U., Withopf B., Ring A., Dugi K.A. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008, 48:1171-1178.
63. Bristol-Myers Squibb. Onglyza (saxagliptin) 5mg film-coated tablets. Summary of Product Characteristics. Last date of revision: 09 October 2009. Available from: [accessed 06.10]. http://emc.medicines.org.uk/medicine/22315/SPC/Onglyza+5mg+film-coated+tablets.
64. Fuchs H., Binder R, Greischel A Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009, 30:229-240.
65. Merck Sharp & Dohme Limited. JANUVIA 100mg film-coated tablets. Summary of Product Characteristics. Last date of revision: 24 November 2009. Available from: [accessed 06.10]. http://emc.medicines.org.uk/medicine/19609/SPC/JANUVIA+100mg+film-coated+tablets/.
66. Novartis Pharmaceuticals UK Ltd. Galvus (vildagliptin) 50mg Tablets. Summary of Product Characteristics. Last date of revision: 24 September 2009. Available from: [accessed 06.10]. http://emc.medicines.org.uk/medicine/20734.
67. Retlich S., Withopf B., Greischel A., Staab A., Jaehde U., Fuchs H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009, 30:422-436.
68. Thomas L., Tadayyon M., Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009, 328:556-563.
69. Gupta R., Walunj S.S., Tokala R.K., Parsa K.V.L., Singh S.K., Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 2009, 10:71-87.
70. Williams-Herman D., Engel S.S., Round E., Johnson J., Golm G.T., Guo H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010, 10:7.
71. Bodmer M., Meier C., Krähenbühl S., Jick S.S., Meier C.R. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008, 31:2086-2091.
72. Foley J.E., Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009, 41:905-909.
73. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205. Sitagliptin Study 024 Group.
74. Chacra A.R., Tan G.H., Apanovitch A., Ravichandran S., List J., Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009, 63:1395-1406. CV181-040 Investigators.
75. Gallwitz B., Häring H.-U. Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2010, 12:1-11.
76. Forst T., Uhlig-Laske B., Ring A., Ritzhaupt A., Graefe-Mody U., Dugi KA The novel, potent, and selective DPP-4 inhibitor BI 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes. Diabetes 2007, 56(Suppl. 1):A157. [abstract].
77. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
78. Linke A., Frank S., Mark M., Klein T The DPP-4 inhibitor linagliptin (BI 1356) improves wound healing in ob/ob mice. Diabetes 2009, 58(Suppl. 1):A161. (abstract).
79. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging class for inflammatory disease?. Trends Pharmacol Sci 2009, 30:600-607.
80. Karim A., Fleck P., Harris S., Weiss M., Zhang W., Mekki Q. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Clin Pharmacol Ther 2008, 83(Suppl. 1):S12.
81. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody U, Woerle H-J. Linagliptin has no pharmacokinetic interaction with digoxin in healthy volunteers. Poster PI-69, presented at the American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 17-20, 2010.
82. He Y.L., Sabo R., Sunkara G., Bizot M.N., Riviere G.J., Leon S., et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007, 47:998-1004.
83. Hansen K.B., Hsiao Y., Xu F., Rivera N., Clausen A., Kubryk M., et al. Highly efficient asymmetric synthesis of sitagliptin. J Am Chem Soc 2009, 131:8798-8804.
84. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., et al. Discovery and Preclinical Profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:5025-5037.
85. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003, 46:2774-2789.
86. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007, 50:2297-2300.
87. Eckhardt M., Langkopf E., Mark M., Tadayyon M., Thomas L., Nar H., et al. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007, 50:6450-6453.